How to Fight Insurance Denials for Adult CAR-T Cell Therapy

CAR-T cell therapy—including Yescarta, Kymriah, Tecartus, Breyanzi, Carvykti, and Abecma—represents one of the most significant advances in treating relapsed or refractory blood cancers. These therapies harvest your own T cells, engineer them to recognize cancer, and infuse them back to attack disease that has failed standard chemotherapy. Despite FDA approval and inclusion in national treatment guidelines, insurers frequently deny CAR-T for cost reasons, citing unproven medical necessity, experimental status, or failure to meet narrow policy criteria. A typical CAR-T course costs $400,000–$500,000 for the product alone, plus facility, monitoring, and complication management—making it a high-stakes target for payer scrutiny. This guide walks you through the most common denial reasons, the clinical evidence insurers must respect, and concrete steps to overturn each type of denial.

Why Insurers Deny CAR-T Cell Therapy

1. "Not medically necessary" or "does not meet plan criteria for line of therapy"

The insurer claims you haven't tried enough prior regimens, or that CAR-T is only approved after three or more lines when your doctor is recommending it in second line. This often ignores updated FDA labels and pivotal trials (ZUMA-7, TRANSFORM, CARTITUDE-4, KarMMa-3) that moved CAR-T into earlier lines for specific high-risk disease.

2. "Investigational/experimental for this indication"

Despite on-label FDA approval, the plan may classify CAR-T as experimental for your specific histology, line of therapy, or prior-treatment combination—especially for newer indications like second-line large B-cell lymphoma, CLL/SLL, or second-line multiple myeloma.

3. "Must fail additional chemotherapy first"

Some policies require exhaustion of salvage regimens (R-ICE, R-DHAP, R-GemOx, polatuzumab-bendamustine-rituximab for lymphoma; daratumumab-pomalidomide-dexamethasone or carfilzomib-lenalidomide-dexamethasone for myeloma) before approving CAR-T, even when your disease is primary refractory or rapidly progressing and further delay risks loss of eligibility.

4. "Does not meet performance status / organ function criteria"

Insurers may cite your ECOG performance status (≥2), cardiac ejection fraction, renal function, or cytopenias as disqualifying, arguing you are "too sick" for CAR-T—without acknowledging that disease progression from delay is what deteriorates performance status, and that carefully selected patients with borderline function benefit when treated promptly.

5. "Bridging chemotherapy / leukapheresis / lymphodepletion not covered separately"

Plans may deny the preparatory steps—bridging therapy to control disease between apheresis and infusion, the leukapheresis procedure itself, or fludarabine-cyclophosphamide lymphodepletion—as "bundled," "experimental," or "not separately reimbursable," even though the CAR-T product label and FACT (Foundation for the Accreditation of Cellular Therapy) standards mandate them.

The Citations Insurers Must Respect

When you appeal, reference these specific guidelines, FDA label expansions, and pivotal trials by name and date. Insurers cannot dismiss on-label FDA approvals or Category 1 NCCN recommendations as "experimental."

Guidelines and consensus statements:

• NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas (2024 version) — lists Yescarta, Kymriah, Breyanzi, and Tecartus as Category 1 (high-level evidence, uniform consensus) for specified indications; explicitly endorses CAR-T in second line for primary refractory or early-relapse (< 12 months) diffuse large B-cell lymphoma (DLBCL).

• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (2024 version) — designates Carvykti and Abecma Category 1 for relapsed/refractory myeloma after ≥2 prior lines including IMiD, proteasome inhibitor, and anti-CD38 antibody; the 2024 update reflects the April 2024 FDA label expansions moving both into second-line post-lenalidomide and anti-CD38.

• American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) guidelines on CAR-T (2023) — support use in accordance with FDA-approved indications and NCCN categories; emphasize timely referral to avoid disease progression that forecloses eligibility.

• European Society for Medical Oncology (ESMO) CAR-T Guidelines (2023) — international consensus affirming standard-of-care status for approved indications.

Pivotal FDA registration trials (cite these by name):

• ZUMA-7 (New England Journal of Medicine, 2022) — randomized Phase 3 trial showing Yescarta superior to salvage chemotherapy plus autologous stem-cell transplant in second-line DLBCL; led to FDA approval April 2022 for relapsed/refractory large B-cell lymphoma after one prior line (primary refractory or early relapse).

• TRANSFORM (New England Journal of Medicine, 2022) — randomized Phase 3 demonstrating Breyanzi improved event-free survival versus standard of care in second-line large B-cell lymphoma; FDA approval June 2022.

• ZUMA-2 (Journal of Clinical Oncology, 2020) — single-arm Phase 2 of Tecartus in relapsed/refractory mantle-cell lymphoma after BTK inhibitor; FDA approval July 2020.

• ZUMA-3 (Blood, 2021) — Tecartus for adult relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL); FDA approval October 2021.

• CARTITUDE-4 (New England Journal of Medicine, 2024) — randomized Phase 3 showing Carvykti superior to pomalidomide-bortezomib-dex or daratumumab-pomalidomide-dex in lenalidomide-refractory myeloma after 1–3 prior lines; FDA approval expansion April 2024 for second-line use.

• KarMMa-3 (Lancet, 2023) — randomized Phase 3 of Abecma versus standard regimens in relapsed/refractory multiple myeloma after 2–4 prior lines; FDA approval expansion April 2024.

• KarMMa (New England Journal of Medicine, 2021) — initial single-arm Phase 2 of Abecma; FDA approval March 2021 for ≥4 prior lines.

• CARTITUDE-1 (Journal of Clinical Oncology, 2021) — single-arm Phase 1b/2 of Carvykti; FDA approval February 2022 for ≥4 prior lines.

• JULIET (New England Journal of Medicine, 2019) — Kymriah registration trial for third-line or later DLBCL; FDA approval May 2018.

• ELARA (Blood, 2022) — Kymriah for third-line or later follicular lymphoma; FDA approval May 2022.

• TRANSCEND-CLL-004 (presented ASH 2023, FDA approval March 2024) — Breyanzi for relapsed/refractory chronic lymphocytic leukemia / small lymphocytic lymphoma.

FDA package inserts (current as of April 2024):

Each product's prescribing information details approved indications, required prior therapies, lymphodepletion regimen (fludarabine 30 mg/m² + cyclophosphamide 300–500 mg/m² on days –5, –4, –3), REMS monitoring, and contraindications. Insurers cannot deny an on-label use without meeting their evidence burden.

CMS National Coverage Determination (NCD) 110.24 (updated 2019):

Medicare covers FDA-approved CAR-T products for on-label indications when delivered at an authorized treatment center (FACT-accredited or equivalent). Many commercial plans mirror CMS policy.

How to Argue Against Each Major Denial Reason

1. Fighting "Not medically necessary" / "Does not meet line-of-therapy criteria"

Why this argument is wrong:

FDA and NCCN explicitly endorse CAR-T in second line for high-risk lymphoma and myeloma. ZUMA-7 and TRANSFORM were designed to replace salvage chemotherapy plus autologous transplant in second-line DLBCL, not follow it. For myeloma, CARTITUDE-4 and KarMMa-3 placed CAR-T after just one prior line if patients are lenalidomide-refractory and anti-CD38-exposed.

Concrete steps:

• Obtain a letter of medical necessity from your hematologist-oncologist detailing your exact prior regimens, dates, responses (complete remission / partial remission / stable disease / progressive disease), and duration of response. For lymphoma, include interim and end-of-treatment PET Deauville scores; for myeloma, minimal residual disease (MRD) and M-protein trends.

• Cite the FDA approval dates and trial names. Example: "Yescarta received FDA approval on April 1, 2022, for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line therapy, based on the ZUMA-7 trial published in the New England Journal of Medicine (2022). My disease is primary refractory to R-CHOP, meeting this on-label indication precisely."

• Attach the relevant NCCN page (B-Cell Lymphomas or Multiple Myeloma guideline) highlighting the Category 1 recommendation and line-of-therapy table. Underline or annotate the row that matches your situation.

• If the insurer's policy language lags behind the FDA label, note this explicitly: "Your policy references 'third-line or later' for DLBCL, but the FDA expanded Yescarta to second line in April 2022. Policies that fail to update within a reasonable period after FDA approval cannot override the regulatory standard of care."

• Explain why further chemotherapy is futile and dangerous. Reference your disease kinetics: "My tumor doubled in size in six weeks on salvage therapy, LDH rose from 340 to 670, and performance status declined from ECOG 0 to ECOG 1. Each cycle of additional ineffective chemotherapy further depletes my T-cell reserve (critical for successful CAR-T manufacturing), increases infection risk, and may render me ineligible due to worsening organ function."

2. Fighting "Investigational / experimental" claims

Why this argument is wrong:

Once FDA approves a product for a specific indication, it is—by definition—no longer investigational for that use. NCCN Category 1 recommendations carry the highest evidence grade. Courts and regulators have consistently held that insurers may not relabel FDA-approved therapies as experimental without presenting contrary peer-reviewed evidence of equal or greater quality.

Concrete steps:

• Lead with the FDA approval letter and package insert. State: "The FDA approved [product name] for [your indication] on [date]. This is an on-label use. Under the Federal Food, Drug, and Cosmetic Act, FDA approval means the agency has determined the product is safe and effective for this indication."

• Cite your state's insurance code or external review standard. Many states (e.g., California, New York, Texas) require that plans cover FDA-approved cancer therapies for on-label uses and that "investigational" determinations be based on authoritative peer-reviewed literature—not cost.

• Invoke NCCN Compendium listing. Medicare and most commercial plans recognize NCCN Category 1 and 2A as meeting "medically accepted indication" standards. Attach the compendium page and state: "NCCN designates this use as Category 1, reflecting high-level evidence and uniform NCCN consensus. Your denial contradicts the national standard-of-care reference your own policy incorporates."

• Point out that clinical trials are closed to standard-of-care patients. If the denial suggests you "try a clinical trial instead," note: "The pivotal trials (ZUMA-7, TRANSFORM, CARTITUDE-4, KarMMa-3) have completed accrual and established CAR-T as the comparator arm. I am not eligible for investigational protocols precisely because CAR-T is now standard therapy."

• Request the insurer's clinical rationale in writing, including the names and credentials of reviewers and any peer-reviewed sources contradicting FDA/NCCN. Most denials lack this; demanding it exposes the absence of an evidence-based review.

3. Fighting "Must fail additional chemotherapy first"

Why this argument is wrong:

Step-therapy (fail-first) requirements are appropriate when therapeutic alternatives have similar efficacy and safety, allowing a trial of less-expensive options. CAR-T is categorically different: it requires viable autologous T cells, adequate performance status, and controlled disease burden. Forcing patients through ineffective salvage regimens depletes T cells (lymphopenic from repeated chemotherapy), deteriorates performance status, and allows disease progression that may preclude manufacturing or infusion. The FDA and NCCN moved CAR-T earlier specifically because outcomes worsen with each additional failed line.

Concrete steps:

• Document prior "failure" clearly. For each mandated regimen the insurer wants you to try, show you already received it (or an equivalent) and failed: "Your policy requires trial of R-ICE before CAR-T. I received two cycles of R-ICE in October 2024; interim PET showed Deauville 5 (no metabolic response), and disease progressed with new lesions. R-ICE has been tried and failed."

• Explain T-cell fitness and the apheresis window. "Leukapheresis must collect adequate CD3+ T cells for manufacturing. Each additional cycle of fludarabine-based or high-dose cytarabine-based chemotherapy causes prolonged lymphopenia. My absolute lymphocyte count is currently 0.8 K/µL. Further chemotherapy risks dropping it below the threshold for successful collection, permanently foreclosing the CAR-T option."

• Cite the ZUMA-7 and TRANSFORM trial designs, which randomized patients in second line to CAR-T versus salvage chemotherapy plus autologous stem-cell transplant—and CAR-T won. "The FDA approval was based on superiority over the very salvage regimens your policy is mandating. Requiring me to fail therapies already proven inferior contradicts the evidence the FDA relied upon."

• Invoke medical urgency. "My disease is rapidly progressive, with a doubling time of four weeks. Delaying CAR-T by 8–12 weeks for additional ineffective chemotherapy will increase tumor burden, worsen performance status from ECOG 1 to ECOG 2 or 3, and likely render me ineligible under your own criteria. This step-therapy requirement is not clinically sound—it is a cost-delay tactic that will harm me."

• Reference your state's step-therapy override laws. Many states (e.g., Illinois, Louisiana, Maryland) allow physicians to request exemptions when the required step is expected to be ineffective, cause harm, or delay necessary treatment. Submit the statutory override form with your appeal.

4. Fighting "Does not meet performance status / organ function criteria"

Why this argument is wrong:

Insurers often impose rigid ECOG ≤1, LVEF ≥50%, or other cutoffs drawn from trial eligibility criteria, ignoring that (a) real-world registry data show benefit in carefully selected ECOG 2 patients, (b) organ dysfunction is often caused by disease burden and improves with disease control, and (c) denying CAR-T guarantees further decline, whereas treating promptly may restore function.

Concrete steps:

• Obtain a multidisciplinary assessment. Your oncologist, cardiologist (for LVEF concerns), nephrologist (for renal function), and pulmonologist (for oxygen requirement or DLCO) should each document that your deficits are manageable and not absolute contraindications. Example: "LVEF 48% is below arbitrary 50% threshold, but cardiologist notes this is due to anemia (Hgb 8.2) and volume depletion from disease; after transfusion and hydration, LVEF improved to 52%. No structural heart disease. Patient is a candidate for CAR-T with cardiac monitoring."

• Cite real-world evidence. The Center for International Blood and Marrow Transplant Research (CIBMTR) registry and published real-world series (e.g., Blood Advances 2023, real-world outcomes of CAR-T in older/comorbid patients) show that ECOG 2 patients with good social support and caregiver availability achieve meaningful responses. Attach relevant abstracts.

• Distinguish FDA label language from absolute contraindications. The Yescarta, Kymriah, and other package inserts list warnings but do not categorically exclude ECOG 2 or LVEF 45–49%. Note: "The FDA label does not prohibit use in ECOG 2 patients; it advises caution and monitoring. Your policy's blanket exclusion is more restrictive than the FDA's and lacks evidentiary support."

• Explain that delay guarantees ineligibility. "My performance status declined from ECOG 0 to ECOG 2 over eight weeks because of disease progression while awaiting your prior authorization. Denying CAR-T now ensures I will become ECOG 3–4 and truly ineligible. Treating now, while I retain adequate organ reserve, offers the only chance to reverse this decline."

• Propose risk-mitigation. Offer to have CAR-T delivered at a high-volume center with on-site ICU, prolonged inpatient monitoring, and preemptive supportive care (transfusions, antimicrobials, cardiac telemetry). Demonstrating a concrete safety plan addresses the insurer's stated concern.

5. Fighting denials of bridging chemotherapy, leukapheresis, or lymphodepletion

Why this argument is wrong:

CAR-T is not a single infusion; it is a multi-step process mandated by the FDA label and FACT standards. Leukapheresis collects your T cells (the raw material). Bridging chemotherapy controls disease during the 3–6 week manufacturing window so your cancer doesn't progress to the point of ineligibility. Lymphodepletion (fludarabine + cyclophosphamide) is specified by dose and schedule in every product label as required conditioning to enable CAR-T expansion. Denying these components while claiming to "cover CAR-T" is illusory coverage.

Concrete steps:

• Attach the FDA package insert sections describing the leukapheresis procedure, recommended bridging, and mandatory lymphodepletion. Highlight: "Administer a lymphodepleting chemotherapy regimen of fludarabine 30 mg/m² intravenously and cyclophosphamide 500 mg/m² intravenously on the fifth, fourth, and third days before infusion." Note: "This is not optional bridging—it is required conditioning per the FDA-approved label."

• Cite FACT standards. The Foundation for the Accreditation of Cellular Therapy requires that authorized CAR-T centers ensure adequate bridging and lymphodepletion as part of the care pathway. Your treatment center can provide a letter confirming these are non-negotiable components.

• Show that leukapheresis is a distinct, separately billable procedure (CPT codes 38205, 38206, 36522) recognized by CMS and commercial fee schedules. "Your denial states leukapheresis is 'bundled,' but CMS assigns separate HCPCS codes and reimbursement. It is a physician-supervised apheresis procedure performed weeks before CAR-T infusion and cannot be bundled into the product code (Q2041 for Yescarta, Q2042 for Kymriah, etc.)."

• Document the clinical necessity of bridging. "At the time of apheresis, my disease burden was [size/stage]. Manufacturing will take 21 days. Without bridging chemotherapy, my oncologist estimates progression to bulky disease >10 cm or performance status decline to ECOG 3, rendering me ineligible for CAR-T infusion. Bridging with polatuzumab-bendamustine-rituximab is standard practice to preserve the CAR-T option." Include a letter from your oncologist with references (e.g., Transplant Cell Ther 2023 bridging therapy review).

• Point out the false economy. "Denying $30,000 of bridging therapy to 'save costs' will result in disease progression that wastes the $150,000 already spent on leukapheresis and manufacturing, plus the inability to deliver the $475,000 CAR-T product you pre-authorized. This denial is penny-wise and pound-foolish."

What We Do

If your insurer has denied CAR-T cell therapy or any component of the CAR-T pathway—leukapheresis, bridging chemotherapy, lymphodepletion, REMS monitoring, or authorized treatment-center care—we help you build and argue the appeal. We work with your oncology and bone-marrow transplant teams to compile your clinical documentation, match it to the specific FDA label and NCCN guideline provisions your insurer must follow, draft detailed letter briefs with embedded trial citations, and represent you through internal appeals, independent external review, and—when necessary—litigation or state insurance-department complaints. Time matters in relapsed or refractory blood cancers; we move fast.

Sources

1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531–2544. (Original ZUMA-1 trial)

2. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640–654. (ZUMA-7)

3. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294–2308. (TRANSFORM)

4. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382(14):1331–1342. (ZUMA-2)

5. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398(10299):491–502. (ZUMA-3)

6. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45–56. (JULIET)

7. Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28(2):325–332. (ELARA)

8. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384(8):705–716. (KarMMa)

9. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388(11):1002–1014. (KarMMa-3)

10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398(10297):314–324. (CARTITUDE-1)

11. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2024;390(4):335–347. (CARTITUDE-4)

12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 1.2024. Accessed April 2026.

13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2024. Accessed April 2026.

14. Stein AS, Ballen KK, Bhatt VR, et al. CAR T-cell therapy for B-cell acute lymphoblastic leukemia. American Society of Hematology Education Program 2023;2023(1):350–358.

15. Nagle SJ, Chhabra S, Schroeder MA, et al. The use of bridging therapy prior to CAR T-cell therapy: Indications, efficacy, and practical considerations. Transplant Cell Ther 2023;29(2):71–78.

16. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 110.24: Chimeric Antigen Receptor (CAR) T-cell Therapy. Updated May 2019.

17. FDA package inserts (accessed April 2026): Yescarta (axicabtagene ciloleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Abecma (idecabtagene vicleucel).

18. Foundation for the Accreditation of Cellular Therapy (FACT). FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration. 8th Edition, 2021.

19. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol 2020;38(27):3119–3128. (Real-world CAR-T outcomes)

20. Jaglowski S. Real-world CAR-T experience: optimizing safety and efficacy. Blood Advances 2023;7(Suppl 1):7–15. (Real-world data including ECOG 2 patients)